Literature DB >> 10202021

DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection.

A D Syrengelas1, R Levy.   

Abstract

Several studies have shown that immunization with DNA, which encodes the idiotypic determinants of a B cell lymphoma, generates tumor-specific immunity. Although induction of antiidiotypic Abs has correlated with tumor protection, the effector mechanisms that contribute to tumor protection have not been clearly identified. This study evaluated the tumor protective effects of humoral and cellular immune mechanisms recruited by idiotype-directed DNA vaccines in the 38C13 murine B cell lymphoma model. Antiidiotypic Abs induced by DNA vaccination supported in vitro complement-mediated cytotoxicity of tumor cells, and simultaneous transfer of tumor cells and hyperimmune sera protected naive animals against tumor growth. However, in vitro stimulation of immune splenocytes with tumor cells failed to induce idiotype-specific cytotoxicity, and following vaccination, depletion of CD4 or CD8 T cell subsets did not compromise protection. Furthermore, protection of naive recipients against tumor challenge could not be demonstrated either by a Winn assay approach or by adoptive transfer of spleen and lymph node cells. Thus, in this experimental model, current evidence suggests that the tumor-protective effects of DNA vaccination can be largely attributed to idiotype-specific humoral immunity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10202021

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Comparison of adenoviruses as oncolytics and cancer vaccines in an immunocompetent B cell lymphoma model.

Authors:  Eric A Weaver; Christopher Y Chen; Shannon M May; Mary E Barry; Michael A Barry
Journal:  Hum Gene Ther       Date:  2011-09-06       Impact factor: 5.695

2.  Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo.

Authors:  Suzanne N Franki; Kristopher K Steward; David J Betting; Kamran Kafi; Reiko E Yamada; John M Timmerman
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

3.  Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study.

Authors:  A A McCormick; S Reddy; S J Reinl; T I Cameron; D K Czerwinkski; F Vojdani; K M Hanley; S J Garger; E L White; J Novak; J Barrett; R B Holtz; D Tusé; R Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-21       Impact factor: 11.205

4.  Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins.

Authors:  Alejandro López-Requena; Oscar R Burrone; Michela Cesco-Gaspere
Journal:  Front Oncol       Date:  2012-11-09       Impact factor: 6.244

Review 5.  Therapeutic vaccines for non-Hodgkin B-cell lymphoma.

Authors:  Javier Briones
Journal:  Clin Transl Oncol       Date:  2008-09       Impact factor: 3.340

6.  Ubiquitin conjugation of hepatitis B virus core antigen DNA vaccine leads to enhanced cell-mediated immune response in BALB/c mice.

Authors:  Jian-Hua Chen; Yong-Sheng Yu; Hong-Hong Liu; Xiao-Hua Chen; Min Xi; Guo-Qing Zang; Zheng-Hao Tang
Journal:  Hepat Mon       Date:  2011-08       Impact factor: 0.660

7.  Chemically linked phage idiotype vaccination in the murine B cell lymphoma 1 model.

Authors:  Tim Roehnisch; Cornelia Then; Wolfgang Nagel; Christina Blumenthal; Todd Braciak; Mariel Donzeau; Thomas Böhm; Carole Bourquin; Fuat Oduncu
Journal:  J Transl Med       Date:  2013-10-23       Impact factor: 5.531

8.  Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells.

Authors:  Agnete B Fredriksen; Inger Sandlie; Bjarne Bogen
Journal:  Front Oncol       Date:  2012-10-30       Impact factor: 6.244

Review 9.  Novel approaches to immunotherapy for B-cell malignancies.

Authors:  Renier J Brentjens
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.945

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.